Sasha Bernatsky, MD, PhD
James º«¹úÂãÎè Professor of Medicine, Division of Clinical Epidemiology and Division of Rheumatology, Department of Medicine
![Sasha Bernatsky, MD, PhD Sasha Bernatsky, MD, PhD](/clinepi/files/clinepi/styles/medium_focal__220_x_220_/public/bernatsky.jpg?itok=rBBOHEFk)
Dr. Bernatsky is a rheumatologist, a James º«¹úÂãÎè professor in the Department of Medicine (Divisions of Rheumatology and Clinical Epidemiology) and a senior scientist affiliated with the Centre for Health Outcomes Research at the Research Institute of the º«¹úÂãÎè Health Centre. Dr. Bernatsky is also affiliated with the º«¹úÂãÎè Environmental Epidemiology Research Group, a network with expertise in pharmacology/toxicology, and environmental sciences. She is a member of the Canadian Urban Environmental Health Research Consortium (CANUE), the Systemic Lupus International Collaborating Clinics, and the Canadian Network for Improved Outcomes in SLE.
She is an established leader in research and knowledge translation in her field, having received numerous awards, including the Arthritis Alliance of Canada’s Knowledge Translation Practice Award. Some of her research focuses on drug exposures in complex chronic diseases and patient outcomes, including morbidity, mortality, and economic impact. She has authored over 450 peer-reviewed articles. An active member of several research networks, Dr. Bernatsky is nominated PI of the Canadian Network for Advanced Interdisciplinary Methods (CAN-AIM) team, initially funded by the Drug Safety and Effectiveness Network, a collaboration between CIHR and Health Canada. CAN-AIM team’s mandate is to provide new, accurate data on the long-term, real-world outcomes of drug therapies. Her work on drug safety and effectiveness includes a novel DSEN-funded national registry of patients receiving biosimilar agents and their legacy drugs. Dr. Bernatsky is also an international leader in research on air pollution and rheumatic disease risk and outcomes, with over a decade of peer-reviewed funding in this area. She is a founding member of REACTRheum, which focuses on the impact of environmental changes on rheumatic diseases.
Ìý
Outcomes in rheumatic diseases, Cancer Risk, comparative effectiveness, database linkage, drug safety and effectiveness, economic analyses, Health Care Technologies, Health Services